NCT01938443 2019-07-12A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid TumorsGlaxoSmithKlinePhase 1 Completed34 enrolled